Vaxcyte Inc. Common Stock vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Vaxcyte Inc. Common Stock trades at $67.27 (market cap $10.51B), while Consumer Discretionary Select Sector SPDR Fund trades at $111.34 (market cap $21.98B). The key difference: Consumer Discretionary Select Sector SPDR Fund is far larger — about 2.1× Vaxcyte Inc. Common Stock's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, Consumer Discretionary Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and Consumer Discretionary Select Sector SPDR Fund for 115 Days on average.
| PCVX | XLY | |
|---|---|---|
Market Cap | $10.51B | $21.98B |
Volume | 2,644,694 | 5,684,050 |
Sector | Health | — |
52-Week High | $73.82 | $124.52 |
52-Week Low | $40.32 | $105.64 |
Typical Hold Time | 0 Days | 115 Days |
Enterprise Value | $9.14B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XLY trades at $112.36 with minimal daily movement (+0.07%), showing technical indecision with a bullish overall signal but bearish moving averages. The ETF has underperformed the broader market in 2026, declining over 7% while consumer staples gained 6.6%. Analyst consensus remains unanimously bullish with a 100% buy rating, though recent news highlights persistent underperformance concerns and consumer spending shifts toward value.
The outlook remains mixed with technical indicators suggesting potential resistance near $113 while fundamental exposure to consumer discretionary spending faces inflation pressures. Key risks include continued market underperformance and consumer sensitivity to economic conditions, though potential catalysts exist from holiday retail growth projections and cyclical sector opportunities.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →